Clinical Trial Update: Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating tislelizumab in combination with anlotinib as second-line therapy for thymoma and thymic carcinoma, and the study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Thymic Carcinoma, Thymoma | Phase 2 | Status: RECRUITING